More than half of Chinese patients with hormone receptor positive (HR+) ductal carcinoma in situ (DCIS) are treated with mastectomy, and usually subjected to postoperative endocrine therapy (ET). The gene discussed is NR4A1; the disease is ductal breast carcinoma in situ.